390 Objectives We report our clinical experience with PSMA targeted radionuclide therapy
of patients with metastatic hormone-refractory prostate cancer in regard to toxicity and …

As the use of radioligand therapy moves earlier in the prostate cancer timeline, minimizing
the absorbed dose to normal organs while maintaining high tumor radiation doses becomes …

Prostate cancer (PC) is the most common cancer and the third most common cause of
cancer-related deaths in men in developed countries (1). In general, PC starts out as an …

Purpose For prostate-specific membrane antigen-directed radioligand therapy (PSMA-
RLT),[177 Lu] Lu-PSMA-617 and [177 Lu] Lu-PSMA-I&T are the currently preferred …

Metastatic castration resistant prostate cancer (mCRPC) is incurable. The expression of the
transmembrane protein prostate-specific membrane antigen (PSMA) is markedly increased …

Abstract Rationale: PSMA-PET-CT enables measuring molecular expression of prostate-
specific membrane antigen (PSMA) in vivo, which is the target molecule of 177 Lu-PSMA …

177Lu-PSMA radioligand therapy is a promising new option for patients with metastasized
castration-resistant prostate cancer, and the spectrum of adverse events with this treatment …

The role of prostate-specific membrane antigen (PSMA) targeted molecular imaging and
radionuclide therapy in prostate cancer is well known. PSMA is also overexpressed in the …

1429 Objectives Radioligand therapy (RLT) with 177Lu-PSMA-617 (Lu-PSMA)(prostate-
specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. There …

61 Objectives Prostate-specific membrane antigen (PSMA) is a potential therapeutic target
in patients with metastatic castration-resistant prostate cancer (mCRPC). To report our initial …